港股異動 | 愛康醫療低開7.49% 擬先舊後新配售若干股 預籌最少1億美元
格隆匯2月21日丨愛康醫療(1789.HK)低開7.49%,報15.06港元,暫成交8.2億港元,最新總市值158億港元。該股去年暴漲逾1倍,今年迄今已累漲逾7成,並於本週三(19日)盤中觸及17.12港元創上市新高。愛康醫療昨晚公佈,公司考慮委任高盛(亞洲)有限責任公司為其建議配售及先舊後新認購安排的獨家配售代理,據此可能按介乎14.65港元至15.15港元的價格配售若干數目的公司每股面值0.01港元的股份,期望籌集所得款項總額最少1億美元。公告還稱,疫情爆發及政府採取的措施可能對截至今年3月31日止三個月的業務產生以下不利影響:(i)若干預期進行關節植入手術的患者押後彼等的手術預約或計劃;(ii)集團的供應鏈(包括採購原材料及成品交付)可能會出現中斷或延誤;及(iii)若干其他供應商及服務供應商可能無法完全恢復其供應或服務能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.